title: Failure of cimetidine as an immunomodulator in cancer patients and normal subjects.
abstract: Our pilot study of cimetidine as an immunomodulator in cancer patients showed no effect at clinically used doses on total blood, neutrophil, lymphocyte, or monocyte count, quantitative immunoglobulin, percentage of E-rosetting cells, phytohemagglutinin responses or delayed hypersensitivity responsiveness. We concluded that in clinically used doses, cimetidine produces no significant immunomodulation either in vivo or in vitro.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D002927:Cimetidine / Q000008:administration & dosage*; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D010865:Pilot Projects; D012882:Skin Tests
chemical_list: D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D002927:Cimetidine